Skip to main content
Top
Published in: Diabetology International 3/2022

25-01-2022 | Diabetic Retinopathy | Case Report

Advanced proliferative diabetic retinopathy and macular edema in acromegaly: a case report and literature review

Authors: Akiko Yuno, Akemi Ikota, Shigeki Koizumi, Yasuo Mashio, Hiroko Imaizumi, Yutaka Sawamura, Akira Shimatsu

Published in: Diabetology International | Issue 3/2022

Login to get access

Abstract

We describe the multimodal management of a patient with proliferative diabetic retinopathy and diabetic macular edema associated with active acromegaly. A 61-year-old Japanese female who had had type 2 diabetic mellitus for > 10 years complained of deteriorated eyesight. She had distinct acromegalic features, and her visual acuity was 0.05 (right) and 0.4 (left) because of sub-capsular cataracts and proliferative diabetic retinopathy with macular edema. Anti-vascular endothelial growth factor treatments, cataract surgeries and retinal direct laser photocoagulation were performed together with gradual glycemic control with basal insulin to prevent worsening of the visual impairment. She was given an injection of a long-acting somatostatin analog (octreotide LAR) and began taking three bolus mealtime insulin shots with basal insulin beginning 1 month before undergoing a trans-sphenoidal adenomectomy. After this successful surgery, her blood glucose levels immediately decreased, and the rapid-acting insulin at mealtimes was discontinued with the observation of normal growth hormone and insulin-like growth factor (IGF)-1 levels, suggesting that her acromegaly was in remission. Her visual acuity improved without a worsening of diabetic retinopathy. Since the increased IGF-1 production in systemic circulation and local vitreous fluids may be one of the aggravating factors for diabetic retinopathy, our patient's acromegaly complicated with severe retinopathy presented an opportunity for multimodal management in close collaboration with an ophthalmologist, neurosurgeon, and endocrinologist. Our literature review revealed that the estimated prevalence of diabetic retinopathy in cases of acromegaly associated with diabetes mellitus is 12.5–42.9%.
Literature
1.
go back to reference Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, et al. Acromegaly. Nat Rev Dis Primers. 2019;5(1):20.CrossRef Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, et al. Acromegaly. Nat Rev Dis Primers. 2019;5(1):20.CrossRef
2.
go back to reference Amemiya T, Toibana M, Hashimoto M, Oseko F, Imura H. Diabetic retinopathy in acromegaly. Ophthalmologica. 1978;176(2):74–80.CrossRef Amemiya T, Toibana M, Hashimoto M, Oseko F, Imura H. Diabetic retinopathy in acromegaly. Ophthalmologica. 1978;176(2):74–80.CrossRef
3.
go back to reference Ballintine EJ, Foxman S, Gorden P, Roth J. Rarity of diabetic retinopathy in patients with acromegaly. Arch Intern Med. 1981;141(12):1625–7.CrossRef Ballintine EJ, Foxman S, Gorden P, Roth J. Rarity of diabetic retinopathy in patients with acromegaly. Arch Intern Med. 1981;141(12):1625–7.CrossRef
4.
go back to reference Azzoug S, Chentli F. Diabetic retinopathy in acromegaly. Indian J Endocrinol Metab. 2014;18(3):407–9.CrossRef Azzoug S, Chentli F. Diabetic retinopathy in acromegaly. Indian J Endocrinol Metab. 2014;18(3):407–9.CrossRef
5.
go back to reference Wu TE, Chen HS. Increased prevalence of proliferative retinopathy in patients with acromegaly. J Chin Med Assoc. 2018;81(3):230–5.CrossRef Wu TE, Chen HS. Increased prevalence of proliferative retinopathy in patients with acromegaly. J Chin Med Assoc. 2018;81(3):230–5.CrossRef
6.
go back to reference Füchtbauer L, Olsson DS, Coopmans EC, Bengtsson BÅ, Norrman LL, Neggers SJCMM, et al. Increased number of retinal vessels in acromegaly. Eur J Endocrinol. 2020;182(3):293–302.CrossRef Füchtbauer L, Olsson DS, Coopmans EC, Bengtsson BÅ, Norrman LL, Neggers SJCMM, et al. Increased number of retinal vessels in acromegaly. Eur J Endocrinol. 2020;182(3):293–302.CrossRef
7.
go back to reference Inokuchi N, Ikeda T, Yasuda F, Shirai S, Uchinori Y. Severe proliferative diabetic retinopathy associated with acromegaly. Br J Ophthalmol. 1999;83(5):629–30.CrossRef Inokuchi N, Ikeda T, Yasuda F, Shirai S, Uchinori Y. Severe proliferative diabetic retinopathy associated with acromegaly. Br J Ophthalmol. 1999;83(5):629–30.CrossRef
8.
go back to reference Tran HA, Petrovsky N, Field AJ. Severe diabetic retinopathy: a rare complication of acromegaly. Intern Med J. 2002;32(1–2):52–4.CrossRef Tran HA, Petrovsky N, Field AJ. Severe diabetic retinopathy: a rare complication of acromegaly. Intern Med J. 2002;32(1–2):52–4.CrossRef
9.
go back to reference Malhotra C. Proliferative diabetic retinopathy in acromegaly. Oman J Ophthalmol. 2010;3(2):96–7.CrossRef Malhotra C. Proliferative diabetic retinopathy in acromegaly. Oman J Ophthalmol. 2010;3(2):96–7.CrossRef
10.
go back to reference Alexopoulou O, Bex M, Kamenicky P, Mvoula AB, Chanson P, Maiter D. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary. 2014;17(1):81–9.CrossRef Alexopoulou O, Bex M, Kamenicky P, Mvoula AB, Chanson P, Maiter D. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary. 2014;17(1):81–9.CrossRef
11.
go back to reference Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124–36.CrossRef Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124–36.CrossRef
12.
go back to reference Wilkinson-Berka JL, Wraight C, Werther G. The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy. Curr Med Chem. 2006;13(27):3307–17.CrossRef Wilkinson-Berka JL, Wraight C, Werther G. The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy. Curr Med Chem. 2006;13(27):3307–17.CrossRef
13.
go back to reference Koller EA, Green L, Gertner JM, Bost M, Malozowski SN. Retinal changes mimicking diabetic retinopathy in two nondiabetic, growth hormone-treated patients. J Clin Endocrinol Metab. 1998;83(7):2380–3.PubMed Koller EA, Green L, Gertner JM, Bost M, Malozowski SN. Retinal changes mimicking diabetic retinopathy in two nondiabetic, growth hormone-treated patients. J Clin Endocrinol Metab. 1998;83(7):2380–3.PubMed
14.
go back to reference Paterson WF, Kelly B, Newman W, Savage MO, Camacho-Hubner C, Dutton GN, et al. Deterioration of visual acuity associated with growth hormone therapy in a child with extreme short stature and high hypermetropia. Horm Res. 2007;67(2):67–72.PubMed Paterson WF, Kelly B, Newman W, Savage MO, Camacho-Hubner C, Dutton GN, et al. Deterioration of visual acuity associated with growth hormone therapy in a child with extreme short stature and high hypermetropia. Horm Res. 2007;67(2):67–72.PubMed
15.
go back to reference Smith LE, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science. 1997;276(5319):1706–9.CrossRef Smith LE, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science. 1997;276(5319):1706–9.CrossRef
16.
go back to reference Tarr JM, Kaul K, Chopra M, Kohner EM, Chibber R. Pathophysiology of diabetic retinopathy. ISRN Ophthalmol. 2013;2013:343560.CrossRef Tarr JM, Kaul K, Chopra M, Kohner EM, Chibber R. Pathophysiology of diabetic retinopathy. ISRN Ophthalmol. 2013;2013:343560.CrossRef
17.
go back to reference Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med. 1999;5(12):1390–5.CrossRef Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med. 1999;5(12):1390–5.CrossRef
18.
go back to reference Vasilaki A, Thermos K. Somatostatin analogues as therapeutics in retinal disease. Pharmacol Ther. 2009;122(3):324–33.CrossRef Vasilaki A, Thermos K. Somatostatin analogues as therapeutics in retinal disease. Pharmacol Ther. 2009;122(3):324–33.CrossRef
19.
go back to reference Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-DeHoff R, Caballero S, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care. 2000;23(4):504–9.CrossRef Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-DeHoff R, Caballero S, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care. 2000;23(4):504–9.CrossRef
20.
go back to reference Boehm BO, Lang GK, Jehle PM, Feldman B, Lang GE. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res. 2001;33(5):300–6.CrossRef Boehm BO, Lang GK, Jehle PM, Feldman B, Lang GE. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res. 2001;33(5):300–6.CrossRef
21.
go back to reference Palii SS, Caballero S Jr, Shapiro G, Grant MB. Medical treatment of diabetic retinopathy with somatostatin analogues. Expert Opin Investig Drugs. 2007;16(1):7–82.CrossRef Palii SS, Caballero S Jr, Shapiro G, Grant MB. Medical treatment of diabetic retinopathy with somatostatin analogues. Expert Opin Investig Drugs. 2007;16(1):7–82.CrossRef
22.
go back to reference Simó-Servat O, Hernández C, Simó R. Somatostatin and diabetic retinopathy: an evolving story. Endocrine. 2018;60(1):1–3.CrossRef Simó-Servat O, Hernández C, Simó R. Somatostatin and diabetic retinopathy: an evolving story. Endocrine. 2018;60(1):1–3.CrossRef
23.
go back to reference Grant M, Russell B, Fitzgerald C, Merimee TJ. Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization. Diabetes. 1986;35(4):416–20.CrossRef Grant M, Russell B, Fitzgerald C, Merimee TJ. Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization. Diabetes. 1986;35(4):416–20.CrossRef
24.
go back to reference Burgos R, Mateo C, Cantón A, Hernández C, Mesa J, Simó R. Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study. Diabetes Care. 2000;23(1):80–3.CrossRef Burgos R, Mateo C, Cantón A, Hernández C, Mesa J, Simó R. Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study. Diabetes Care. 2000;23(1):80–3.CrossRef
25.
go back to reference van Setten G, Brismar K, Algvere P. Elevated intraocular levels of insulin-like growth factor I in a diabetic patient with acromegaly. Orbit. 2002;21(2):161–7.CrossRef van Setten G, Brismar K, Algvere P. Elevated intraocular levels of insulin-like growth factor I in a diabetic patient with acromegaly. Orbit. 2002;21(2):161–7.CrossRef
26.
go back to reference Ruberte J, Ayuso E, Navarro M, Carretero A, Nacher V, Haurigot V, et al. Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. J Clin Investig. 2004;113(8):1149–57.CrossRef Ruberte J, Ayuso E, Navarro M, Carretero A, Nacher V, Haurigot V, et al. Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. J Clin Investig. 2004;113(8):1149–57.CrossRef
Metadata
Title
Advanced proliferative diabetic retinopathy and macular edema in acromegaly: a case report and literature review
Authors
Akiko Yuno
Akemi Ikota
Shigeki Koizumi
Yasuo Mashio
Hiroko Imaizumi
Yutaka Sawamura
Akira Shimatsu
Publication date
25-01-2022
Publisher
Springer Nature Singapore
Published in
Diabetology International / Issue 3/2022
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-022-00571-4

Other articles of this Issue 3/2022

Diabetology International 3/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine